2025年12月8日,Kymera治疗公司内部人员出售了8 900万美元库存,因为尽管最近库存激增,该公司报告季度损失和收入缺损。 Kymera Therapeutics insiders sold $8.9M in stock on Dec. 8, 2025, as the company reported a quarterly loss and missed revenue, despite a recent stock surge.

2025年12月8日,包括CEO Nello Mainolfi和董事Jeffrey Albers在内的多个Kymera治疗内幕人士出售股票,Mainolfi的交易总额达890万美元。 On December 8, 2025, multiple Kymera Therapeutics insiders, including CEO Nello Mainolfi and director Jeffrey Albers, sold shares, with Mainolfi's transaction totaling $8.9 million. 该股因成交量大上涨至94.30美元，季度每股亏损0.90美元，未达预期，收入远低于预期276万美元。 The stock rose to $94.30 on heavy volume amid a quarterly loss of $0.90 per share, missing estimates, and revenue of $2.76 million far below projections. 该公司开发用于蛋白质降解的小型分子药物,市场上限为67.8亿美元,尽管最近库存激增,达到12个月最高水平103美元,但仍继续报告损失。 The company, developing small molecule drugs for protein degradation, has a market cap of $6.78 billion and continues to report losses despite a recent stock surge to a 12-month high of $103.00.